Back to top
more

Pharming Group (PHGUF)

(Delayed Data from OTC)

$0.95 USD

0.95
NA

0.00 (0.00%)

Updated Apr 17, 2024 12:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for PHGUF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Pharming Group NV falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 213 208 192 192 74
Receivables 46 28 30 33 29
Notes Receivable 0 0 0 0 0
Inventories 57 42 27 20 16
Other Current Assets 0 0 0 0 0
Total Current Assets 316 278 249 245 119
Net Property & Equipment 10 10 13 11 10
Investments & Advances 10 10 9 7 6
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 30 23 21 30 32
Intangibles 71 75 84 88 79
Deposits & Other Assets 2 1 1 0 3
Total Assets 463 426 397 389 256
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 73 54 42 44 41
Current Portion Long-Term Debt 2 2 2 2 51
Current Portion Capital Leases 4 3 2 2 2
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 23 20
Total Current Liabilities 78 60 47 71 114
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 137 132 139 139 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 30 30 18 8 5
Other Non-Current Liabilities 0 0 0 0 19
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 244 221 204 219 138
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 8 8 7 7 7
Capital Surplus 478 462 455 453 439
Retained Earnings -265 -256 -273 -295 -333
Other Equity -2 -9 3 5 4
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 219 205 193 171 117
Total Liabilities & Shareholder's Equity 463 426 397 389 256
Total Common Equity 219 205 193 171 117
Shares Outstanding 652.40 652.40 625.80 625.80 625.80
Book Value Per Share 0.34 0.31 0.31 0.27 0.19

Fiscal Year End for Pharming Group NV falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 213 198 -99,999 185
Receivables NA 46 41 NA 33
Notes Receivable NA 0 NA NA 0
Inventories NA 57 53 NA 48
Other Current Assets NA 0 NA NA 0
Total Current Assets NA 316 292 NA 266
Net Property & Equipment NA 10 10 NA 10
Investments & Advances NA 10 9 NA 10
Other Non-Current Assets NA 0 NA NA 0
Deferred Charges NA 30 27 NA 29
Intangibles NA 71 70 NA 76
Deposits & Other Assets NA 2 2 NA 1
Total Assets NA 463 436 NA 423
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 NA NA 0
Accounts Payable NA 73 63 NA 53
Current Portion Long-Term Debt NA 2 2 NA 2
Current Portion Capital Leases NA 4 4 NA 4
Accrued Expenses NA 0 NA NA 0
Income Taxes Payable NA 0 NA NA 0
Other Current Liabilities NA 0 NA NA 0
Total Current Liabilities NA 78 68 NA 59
Mortgages NA 0 NA NA 0
Deferred Taxes/Income NA 0 NA NA 0
Convertible Debt NA 137 130 NA 134
Long-Term Debt NA 0 NA NA 0
Non-Current Capital Leases NA 30 29 NA 31
Other Non-Current Liabilities NA NA NA 0
Minority Interest (Liabilities) NA 0 NA NA 0
Total Liabilities NA 244 227 NA 224
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 NA NA 0
Common Stock (Par) NA 8 8 NA 8
Capital Surplus NA 478 476 NA 463
Retained Earnings NA -265 -263 NA -266
Other Equity NA -2 -11 NA -5
Treasury Stock NA 0 NA NA 0
Total Shareholder's Equity NA 219 210 NA 199
Total Liabilities & Shareholder's Equity NA 463 436 NA 423
Total Common Equity 0 219 100,209 0 199
Shares Outstanding 652.40 652.40 652.40 652.40 652.40
Book Value Per Share 0.00 0.34 153.60 0.00 0.31